Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 5Completed 5Active not recruiting 4Withdrawn 2Not yet recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 23Breast 11Plasma cell 7Lymphoid 7Gastrointestinal 4Thoracic 3Other solid neoplasm 3Genitourinary 3Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Myeloid 1Head & Neck 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 26Temozolomide 23Doxorubicin 22Radiotherapy 21Filgrastim 19Ifosfamide 15pazopanib 14Gemcitabine 14Etoposide 13Bevacizumab 13Irinotecan 12Cisplatin 12Magnetic Resonance Spectroscopy 11Imatinib Mesylate 11Granulocyte Colony-Stimulating Factor 11Carboplatin 11Radiation 9Methotrexate 9pembrolizumab 8fludarabine phosphate 8Rituximab 8Paclitaxel 8Docetaxel 8Cyclosporine 8Busulfan 8Antilymphocyte Serum 8fludarabine 7Vincristine 7Radiotherapy, Intensity-Modulated 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × liposomal doxorubicin × Sarcoma × Clear all
NCT02331251 2018-07-02

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Western Regional Medical Center

Phase 1/2 Terminated
81 enrolled
BreastGastrointestinalSarcomaThoracic

Breast Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡